Tissue Engineering Part B-Reviews is a premier academic journal published by MARY ANN LIEBERT, INC, focusing on the interdisciplinary field of tissue engineering and regenerative medicine. With an impressive impact factor that places it in the Q1 category across multiple relevant fields—including Biochemistry, Bioengineering, Biomaterials, and Biomedical Engineering—this journal provides a vital platform for researchers and professionals to disseminate cutting-edge findings and comprehensive reviews. Covering a vast scope from 2008 to 2024, the journal is committed to advancing knowledge in the application of engineering principles to biological tissues, making it an indispensable resource for those at the forefront of biomedical innovation. While the journal does not currently offer open access options, its rigorous peer review process ensures high-quality contributions that are essential for academic and practical advancements. The journal's rankings in Scopus reflect its significance, catering to a diverse audience of students, researchers, and practitioners seeking the latest insights in this dynamic field.

Regenerative Biomaterials, published by Oxford University Press, serves as a premier platform for the dissemination of innovative research in the rapidly evolving field of biomaterials. Since its inception in 2014, this esteemed open-access journal has fostered a collaborative and diverse scientific community, providing free access to impactful articles that enhance our understanding of regenerative medicine and tissue engineering. With a commendable impact factor and ranking within the top quartiles of both Biomedical Engineering and Materials Science, it is recognized for its rigorous peer-review process and high-quality publications. The journal aims to bridge the gap between fundamental research and applied sciences, promoting advanced studies that contribute to clinical applications and regeneration strategies. Researchers, practitioners, and students alike are encouraged to engage with the journal’s content to foster interdisciplinary collaboration and drive future innovations in the biomaterials domain.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

ACS Biomaterials Science & Engineering, published by the American Chemical Society, serves as a premier platform for the latest advancements and research in the fields of biomaterials and biomedical engineering. With an impressive impact factor and a strong reputation reflected in its ranking—Q2 in Biomaterials and Q1 in Biomedical Engineering—the journal attracts a diverse and engaged readership. Since its inception in 2015, it has aimed to foster innovation by publishing high-quality research articles, reviews, and perspectives on the synthesis, characterization, and application of biomaterials. Researchers and professionals benefit from the journal's rigorous peer-review process and its focus on translational science, making it essential for those looking to stay at the forefront of biomaterials research. Located in Washington, DC, USA, the journal plays a pivotal role in connecting academic and industrial sectors, ultimately driving advancements that impact biomedicine and related fields.

Immunotherapy, published by Future Medicine Ltd, is a leading journal focused on the evolving field of immunotherapy within the realms of immunology, oncology, and allergy. With an ISSN of 1750-743X and an E-ISSN of 1750-7448, this academic journal has been at the forefront of groundbreaking research since 2009, and continues to illuminating insights in a landscape critical for the development of innovative therapeutic strategies through 2024. Positioned within Q2 and Q3 quartiles in various relevant categories, the journal ranks commendably in Scopus metrics, exhibiting robust engagement and relevance in Oncology and Immunology. It serves as an essential resource for researchers, clinicians, and students eager to stay abreast of advancements in immunotherapy, while also providing an open platform for sharing impactful studies. By disseminating high-quality research, Immunotherapy fosters a global dialogue among professionals and contributes significantly to the scientific community's collective knowledge on the increasing role of immune-based therapies in disease management.

Biomaterials Advances is a premier journal published by Elsevier, dedicated to the rapidly evolving field of biomaterials. Established in the United Kingdom, this open-access journal aims to disseminate high-quality, peer-reviewed research that explores innovative biomaterial designs and their applications in bioengineering and biomedical engineering. With an impressive 2023 impact factor reflected in its Q1 rankings across multiple categories—including Bioengineering, Biomaterials, and Biomedical Engineering—Biomaterials Advances stands out as a critical platform for scholars and practitioners faced with advancing technologies and methodologies in the realm of materials science. Covering a broad range of topics, from biocompatibility to tissue engineering, this journal provides an inclusive forum for researchers seeking to contribute to the field. Its Scopus rankings further affirm its position as a leading resource, with notable standings in Biomedical Engineering (Rank #13), Biomaterials (Rank #8), and Bioengineering (Rank #11), all within the top percentiles. Researchers and students alike are encouraged to contribute and engage with the latest findings and innovations in biomaterials through this valuable publication.

Asian Journal of Pharmaceutical Sciences is a prestigious open-access journal published by Shenyang Pharmaceutical University, dedicated to advancing research and developments in the field of pharmaceutical sciences. Since its inception in 2009, the journal has successfully converged a wealth of knowledge and innovation, demonstrating an impressive track record with its open access model adopted in 2013, ensuring global dissemination of crucial research findings. With an outstanding impact factor and consistently ranked in the Q1 category for both Pharmaceutical Science and Pharmacology in 2023, it ranks among the top journals in its field, as evidenced by its impressive Scopus rankings—4th out of 183 in Pharmaceutical Science and 10th out of 313 in Pharmacology, showcasing its high relevance and credibility (98th and 96th percentiles respectively). Researchers, professionals, and students can access a diverse array of articles that encompass groundbreaking studies, reviews, and reports, solidifying the journal's position as a vital resource for anyone engaged in pharmaceutical research. With its commitment to quality and accessibility, Asian Journal of Pharmaceutical Sciences plays an essential role in fostering innovation and collaboration within the global scientific community.

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Nano Today is a prestigious journal published by ELSEVIER SCI LTD that stands at the forefront of nanoscience and nanotechnology research. With an impact factor that underscores its significance, this journal has achieved remarkable rankings in several key categories as of 2023, including Q1 positions in Bioengineering, Biomedical Engineering, Biotechnology, Materials Science, and Pharmaceutical Science, making it an essential resource for scholars and professionals alike. ISSN 1748-0132 and E-ISSN 1878-044X, the journal serves as a vital platform for disseminating cutting-edge research findings and innovative applications in the field. Although open access options are not available, the journal's rich repository of peer-reviewed articles provides invaluable insights into the latest advancements in nanotechnologies. Based in the Netherlands, Nano Today not only connects a global network of researchers but also propels forward the conversation on the transformative potential of nanomaterials across multiple disciplines. With a commitment to advancing knowledge and fostering innovation, Nano Today is an indispensable tool for academics and practitioners dedicated to pushing the boundaries of scientific exploration.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.